Uys Joachim D, LaLumiere Ryan T
Department of Neurosciences, Medical University of South Carolina, 173 Ashley Ave, Charleston, SC 29425, USA.
CNS Neurol Disord Drug Targets. 2008 Nov;7(5):482-91. doi: 10.2174/187152708786927868.
Considerable research into the neurobiology of cocaine addiction has shed light on the role of glutamate. Findings from models of relapse to cocaine-seeking indicate that the glutamatergic system is critically involved, as glutamate levels in the nucleus accumbens increase during reinstatement and glutamate receptor activation is necessary for reinstatement to drug-seeking. Thus, it would seem beneficial to block the increased glutamate release, but full antagonists of ionotropic glutamate receptors produce undesirable side effects. Therefore, modulation of glutamatergic transmission would be advantageous and provide novel pharmacotherapeutic avenues. Pharmacotherapies have been developed that have the potential to modulate excessive glutamatergic transmission through ionotropic and metabotropic (mGluR) glutamate receptors. Compounds that modulate glutamatergic transmission through ionotropic glutamate receptors include the non-competitive N-methyl-D-aspartic acid antagonists, amantadine and memantine, and the partial N-methyl-D-aspartic acid agonist d-cycloserine. They have shown promise in preclinical models of cocaine addiction. The mGluR2/3 agonist LY379268 is effective in inhibiting cocaine seeking in preclinical animal models and could decrease stress-induced relapse due to its anxiolytic effects. Similarly, the mGluR1/5 antagonists, 2-methyl-6-(phenylethynyl)pyridine and 3-[2-methyl-4-thiazolyl)ethynyl]pyridine, have shown to be effective in preclinical models of cocaine addiction. The cysteine pro-drug, N-acetylcysteine, restores the inhibitory tone on presynaptic glutamate receptors and has been effective in reducing cue-induced craving and cocaine use in humans. Furthermore, anticonvulsants, such as topiramate or lamotrigine, have shown efficacy in treating cocaine dependence or reducing relapse in humans. Future pharmacotherapy may focus on manipulating signal transduction proteins and pathways, which include Homer/N-methyl-D-aspartic acid complexes, to provide effective treatment for cocaine addiction.
对可卡因成瘾神经生物学的大量研究揭示了谷氨酸的作用。可卡因觅药复发模型的研究结果表明,谷氨酸能系统至关重要,因为在复吸过程中伏隔核中的谷氨酸水平会升高,且谷氨酸受体激活是复吸觅药所必需的。因此,阻断谷氨酸释放增加似乎有益,但离子型谷氨酸受体的完全拮抗剂会产生不良副作用。所以,调节谷氨酸能传递将具有优势,并提供新的药物治疗途径。已经开发出了一些药物疗法,它们有可能通过离子型和代谢型(mGluR)谷氨酸受体调节过度的谷氨酸能传递。通过离子型谷氨酸受体调节谷氨酸能传递的化合物包括非竞争性N-甲基-D-天冬氨酸拮抗剂金刚烷胺和美金刚,以及部分N-甲基-D-天冬氨酸激动剂d-环丝氨酸。它们在可卡因成瘾的临床前模型中显示出了前景。mGluR2/3激动剂LY379268在临床前动物模型中能有效抑制可卡因觅药行为,并且由于其抗焦虑作用可减少应激诱导的复吸。同样,mGluR1/5拮抗剂2-甲基-6-(苯乙炔基)吡啶和3-[2-甲基-4-噻唑基)乙炔基]吡啶在可卡因成瘾的临床前模型中也已显示出有效性。半胱氨酸前体药物N-乙酰半胱氨酸可恢复突触前谷氨酸受体的抑制性张力,并已有效减少人类线索诱导的渴望和可卡因使用。此外,抗惊厥药,如托吡酯或拉莫三嗪,在治疗人类可卡因依赖或减少复吸方面已显示出疗效。未来的药物治疗可能会专注于操纵信号转导蛋白和途径,其中包括Homer/N-甲基-D-天冬氨酸复合物,以为可卡因成瘾提供有效的治疗。